How to Get Cimzia (Certolizumab Pegol) Covered by Aetna in Michigan: Decision Tree, Forms & Appeals Guide
Answer Box: Quick Path to Cimzia Coverage with Aetna in Michigan
To get Cimzia (certolizumab pegol) covered by Aetna in Michigan: First, ensure you have documented failure or intolerance to preferred biosimilar alternatives (adalimumab or infliximab biosimilars) and completed TB/hepatitis B screening within 12 months. Submit prior authorization through CVS Specialty Pharmacy with complete clinical documentation from a specialist. If denied, file internal appeal within 60 days, then Michigan DIFS external review within 127 days of final denial. Start today: Contact your specialist to document biosimilar trial history and order required screening tests.
Table of Contents
- How to Use This Decision Tree
- Eligibility Triage: Do You Qualify?
- If "Likely Eligible": Document Checklist & Submission
- If "Possibly Eligible": Tests to Request
- If "Not Yet Eligible": Alternative Options
- If Denied: Michigan Appeal Process
- Coverage Requirements at a Glance
- Common Denial Reasons & How to Fix Them
- Costs & Patient Support Programs
- FAQ: Aetna Cimzia Coverage in Michigan
How to Use This Decision Tree
This guide helps patients and clinicians navigate Aetna's prior authorization requirements for Cimzia in Michigan. Work through each section in order—the eligibility triage will determine your next steps, whether that's gathering documentation, requesting additional tests, or preparing for an appeal.
Important: Cimzia requires prior authorization with all Aetna plans and is classified as non-preferred, meaning you'll need to meet step therapy requirements before approval. CVS Specialty Pharmacy typically handles fulfillment once approved.
Eligibility Triage: Do You Qualify?
Answer these questions to determine your approval likelihood:
✅ Likely Eligible if you have ALL of these:
- FDA-approved diagnosis: moderate-to-severe Crohn's disease, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, plaque psoriasis, or polyarticular juvenile idiopathic arthritis (age 4+)
- Documented failure, intolerance, or contraindication to preferred biosimilars (adalimumab or infliximab biosimilars)
- Negative TB screening (tuberculin skin test or IGRA) within 12 months
- Negative hepatitis B screening (HBsAg and anti-HBc) within 12 months
- Specialist involvement (rheumatologist, gastroenterologist, or dermatologist)
⚠️ Possibly Eligible if you have:
- Correct diagnosis but missing some documentation
- Partial biosimilar trial history
- Screening tests older than 12 months
- Primary care provider willing to coordinate with specialist
❌ Not Yet Eligible if:
- No documented biosimilar trials
- Missing required screening tests
- Diagnosis doesn't match FDA-approved indications
- Concurrent use of other targeted immunomodulators
If "Likely Eligible": Document Checklist & Submission
Required Documentation
- Clinical notes with diagnosis, ICD-10 codes, and disease severity assessment
- Prior therapy history with specific drug names, dates, durations, and reasons for discontinuation
- TB screening results (negative TST or IGRA within 12 months)
- Hepatitis B screening (negative HBsAg and anti-HBc within 12 months)
- Specialist consultation notes or prescriber specialty verification
- Current lab results relevant to monitoring (CBC, liver function if indicated)
Submission Process
- Download forms: Get the Aetna Medicare Cimzia precertification form or commercial plan equivalent
- Complete enrollment: Submit CVS Specialty enrollment form for your condition
- Submit via: Availity portal, EMR integration, or fax to CVS Specialty
- Timeline: Standard decisions within 30-45 days; expedited within 72 hours for urgent cases
Tip: Attach copies of both sides of insurance cards and ensure prescriber provides physical signature (no stamps accepted).
If "Possibly Eligible": Tests to Request
Missing Documentation Checklist
- Request TB screening: Order tuberculin skin test or interferon-gamma release assay if older than 12 months
- Update hepatitis B tests: HBsAg and anti-HBc within past year
- Document biosimilar trials: Request records from previous providers showing adalimumab or infliximab biosimilar attempts
- Specialist referral: Schedule consultation if not already established
- Timeline to reapply: 2-4 weeks after completing missing requirements
What to Track
- Test result dates (screening must be current)
- Prior therapy start/stop dates with specific reasons for discontinuation
- Specialist appointment scheduling and documentation requests
If "Not Yet Eligible": Alternative Options
Step Therapy Alternatives to Try First
- Adalimumab biosimilars: adalimumab-atto (Amjevita), adalimumab-adbm (Cyltezo)
- Infliximab biosimilars: infliximab-dyyb (Inflectra), infliximab-abda (Renflexis)
- Conventional DMARDs: methotrexate, sulfasalazine (if not already tried)
Preparing for Exception Requests
- Document contraindications to preferred agents
- Gather evidence of urgent medical need
- Request specialist letter supporting Cimzia as first-line therapy
- Consider enrollment in manufacturer support programs while preparing documentation
If Denied: Michigan Appeal Process
Level 1: Internal Appeal with Aetna
- Deadline: 60 days from denial notice
- How to file: Submit via Aetna member portal or written appeal
- Decision timeline: 30 days standard; 72 hours expedited
- Required: Address specific denial reasons with additional clinical evidence
Level 2: Peer-to-Peer Review
- When: If internal appeal denied
- Process: Direct physician-to-physician discussion
- Timeline: Usually scheduled within 5-10 business days
- Preparation: Have specialist available with clinical rationale
Level 3: Michigan DIFS External Review
- Deadline: 127 days after Aetna's final internal denial
- How to file: DIFS External Review Request form online, email, fax, or mail
- Standard timeline: Decision within 56 days (up to 84 days in complex cases)
- Expedited timeline: 72 hours with physician attestation of medical urgency
- Binding decision: DIFS ruling is final and enforceable
Michigan-specific advantage: DIFS external reviews are conducted by independent medical experts and have strong consumer protections under the Patient's Right to Independent Review Act.
Contact DIFS: 877-999-6442 for assistance with the external review process.
Coverage Requirements at a Glance
| Requirement | Details | Source |
|---|---|---|
| Prior Authorization | Required for all Aetna plans | Aetna 2025 Precert List |
| Formulary Status | Non-preferred specialty tier | Aetna Specialty Drug List |
| Step Therapy | Must try preferred biosimilars first | Aetna Medical Policy |
| Specialist Requirement | Rheumatologist, gastroenterologist, or dermatologist | Aetna PA forms |
| TB Screening | Negative within 12 months | FDA labeling requirements |
| Hepatitis B Screening | HBsAg and anti-HBc negative | FDA labeling requirements |
| Quantity Limits | Maintenance dosing restrictions apply | Aetna Quantity Limits |
Common Denial Reasons & How to Fix Them
| Denial Reason | How to Overturn |
|---|---|
| Missing TB screening | Submit negative TST or IGRA results within 12 months |
| No documented biosimilar failure | Provide detailed records of adalimumab/infliximab biosimilar trials with dates and outcomes |
| Non-specialist prescriber | Transfer prescription to rheumatologist, gastroenterologist, or dermatologist |
| Incomplete clinical documentation | Submit comprehensive notes with diagnosis, severity, and treatment rationale |
| Missing hepatitis B screening | Provide current HBsAg and anti-HBc test results |
| Concurrent immunosuppressant use | Adjust therapy to avoid contraindicated combinations |
Costs & Patient Support Programs
CIMplicity Program (Manufacturer Support)
UCB offers the CIMplicity program providing:
- Benefits investigation and prior authorization assistance
- Copay support for eligible commercially insured patients
- Injection training and adherence support
- Nurse and pharmacist consultations
Enrollment: Visit cimplicitycares.com or ask your provider to enroll you during the prescription process.
CVS Specialty Patient Support
- Refill reminders and adherence monitoring
- Clinical consultations with specialty pharmacists
- Coordination with manufacturer programs
- Home delivery and injection training
List price: Approximately $5,999 for a two-syringe maintenance pack, though most patients pay significantly less with insurance coverage and support programs.
FAQ: Aetna Cimzia Coverage in Michigan
Q: How long does Aetna prior authorization take for Cimzia in Michigan? A: Standard decisions take 30-45 days. Expedited reviews for urgent cases are completed within 72 hours.
Q: What if Cimzia isn't on my Aetna formulary? A: Submit a formulary exception request with clinical justification for why preferred alternatives aren't suitable.
Q: Can I request an expedited appeal in Michigan? A: Yes. Both Aetna internal appeals and Michigan DIFS external reviews offer expedited processes (72 hours) with physician attestation of medical urgency.
Q: Does step therapy apply if I tried biosimilars outside Michigan? A: Yes. Document out-of-state biosimilar trials with medical records showing dates, outcomes, and reasons for discontinuation.
Q: What happens if DIFS overturns Aetna's denial? A: The decision is binding. Aetna must provide coverage as directed by the independent review organization.
Q: Can my doctor file appeals for me? A: Yes. Michigan law allows physicians or authorized representatives to file appeals with patient consent.
At Counterforce Health, we help patients and clinicians turn insurance denials into successful appeals by providing evidence-backed documentation that addresses payer-specific requirements. Our platform analyzes denial letters and creates targeted rebuttals using the right clinical evidence and procedural requirements for each situation.
From our advocates: "We've seen Cimzia appeals succeed most often when patients provide comprehensive documentation of biosimilar failures alongside current screening results. The key is addressing every denial reason with specific clinical evidence rather than general medical necessity arguments."
Getting Cimzia covered by Aetna in Michigan requires patience and thorough documentation, but the state's consumer-friendly external review process provides strong protections when clinical evidence supports medical necessity. Work closely with your specialist to gather complete documentation, and don't hesitate to use Michigan's DIFS external review if internal appeals are unsuccessful.
Disclaimer: This information is for educational purposes only and doesn't constitute medical or legal advice. Coverage decisions depend on individual circumstances and plan specifics. For assistance with insurance appeals in Michigan, contact DIFS at 877-999-6442 or visit Michigan.gov/DIFS.
Sources & Further Reading
- Aetna 2025 Prior Authorization List (PDF)
- Aetna Medical Policy: Inflammatory Conditions
- CVS Specialty Enrollment Forms
- Michigan DIFS External Review Process
- CIMplicity Patient Support Program
- Cimzia FDA Prescribing Information
Powered by Counterforce Health—AI that turns drug denials into evidence-based appeals patients and clinicians can submit today.